Sharad Goyal1, Alan Cohler, Jayne Camporeale, Venkat Narra, Ning J Yue. 1. Department of Radiation Oncology, The Cancer Institute of New Jersey UMDNJ/Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, NJ 08903, USA. goyalsh@umdnj.edu
Abstract
PURPOSE: Orbital manifestations of non-Hodgkin's lymphoma (NHL) are rare and accounts for only 1% of all cases of NHL. There have been no reports of treating orbital lymphoma using intensity-modulated radiotherapy (IMRT). MATERIALS AND METHODS: Four patients were treated at our institution for orbital lymphoma using IMRT. Radiotherapy (RT) plans using wedged pair fields were developed for comparison. Clinical results using IMRT are presented and a dosimetric analysis between IMRT and RT was performed. RESULTS: All patients had a complete response based on their physical examinations and post-IMRT imaging. Symptoms that had been present at initial presentation resolved in all patients during the course of the treatment. All four patients experienced only grade 1 dry eye syndrome and keratitis. The average dose to the contralateral orbit, lacrimal gland, and lens were all significantly reduced (P < 0.01) in IMRT patients as compared to the RT patients. IMRT reduced the V5 and V10 for the contralateral lens, orbit, and lacrimal gland and the optic chiasm (P < 0.05). CONCLUSION: IMRT is feasible when treating orbital lymphoma and reduces dose to critical structures while providing excellent dose coverage of target volumes. IMRT offers patients with orbital lymphoma excellent clinical outcomes, similar to conventional RT, with no increased toxicity.
PURPOSE: Orbital manifestations of non-Hodgkin's lymphoma (NHL) are rare and accounts for only 1% of all cases of NHL. There have been no reports of treating orbital lymphoma using intensity-modulated radiotherapy (IMRT). MATERIALS AND METHODS: Four patients were treated at our institution for orbital lymphoma using IMRT. Radiotherapy (RT) plans using wedged pair fields were developed for comparison. Clinical results using IMRT are presented and a dosimetric analysis between IMRT and RT was performed. RESULTS: All patients had a complete response based on their physical examinations and post-IMRT imaging. Symptoms that had been present at initial presentation resolved in all patients during the course of the treatment. All four patients experienced only grade 1 dry eye syndrome and keratitis. The average dose to the contralateral orbit, lacrimal gland, and lens were all significantly reduced (P < 0.01) in IMRT patients as compared to the RT patients. IMRT reduced the V5 and V10 for the contralateral lens, orbit, and lacrimal gland and the optic chiasm (P < 0.05). CONCLUSION: IMRT is feasible when treating orbital lymphoma and reduces dose to critical structures while providing excellent dose coverage of target volumes. IMRT offers patients with orbital lymphoma excellent clinical outcomes, similar to conventional RT, with no increased toxicity.
Authors: T W Bolek; H M Moyses; R B Marcus; L Gorden; R L Maiese; N M Almasri; N P Mendenhall Journal: Int J Radiat Oncol Biol Phys Date: 1999-04-01 Impact factor: 7.038
Authors: Ping Zhou; Andrea K Ng; Barbara Silver; Sigui Li; Ling Hua; Peter M Mauch Journal: Int J Radiat Oncol Biol Phys Date: 2005-05-31 Impact factor: 7.038
Authors: Sylvie Martinet; Mahmut Ozsahin; Yazid Belkacémi; Christine Landmann; Philip Poortmans; Christoph Oehlere; Luciano Scandolaro; Marco Krengli; Philippe Maingon; Raymond Miralbell; Gabriela Studer; Bruno Chauvet; Simone Marnitz; Abderrahim Zouhair; René Olivier Mirimanoff Journal: Int J Radiat Oncol Biol Phys Date: 2003-03-15 Impact factor: 7.038
Authors: Iñigo San-Miguel; Ruth Carmona; Luis Luque; Raquel Cabrera; Marta Lloret; Francisco Rutllan; Pedro Carlos Lara Journal: Rep Pract Oncol Radiother Date: 2016-05-07
Authors: Robert F Hobbs; Sébastien Baechler; Richard L Wahl; Bin He; Hong Song; Caroline E Esaias; Eric C Frey; Heather Jacene; George Sgouros Journal: J Nucl Med Date: 2010-02-11 Impact factor: 10.057
Authors: Victor H F Lee; Sherry C Y Ng; Cheuk Wai Choi; Mai Yee Luk; To Wai Leung; Gordon K H Au; Dora L W Kwong Journal: Radiat Oncol Date: 2012-11-26 Impact factor: 3.481